MAZE Valuation Metrics
FCF$-112.73M
FCF Growth Rate—
EPS Growth (CAGR)—
WACC10.00%
Maze Therapeutics Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Maze Therapeutics Inc
Current Price
$25.56
-3.29%Profile
Valuation (TTM)
Market Cap$1.27B
P/E-10.37
EV—
P/B3.58
Shares Out49.71M
P/Sales63.53
Revenue$20.00M
EV/EBITDA—
Maze Therapeutics Inc (MAZE) Valuation
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →MAZE Valuation & Fair Value Analysis
Maze Therapeutics Inc (MAZE) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The price-to-earnings (P/E) ratio is -10.37. Price-to-book ratio is 3.58. Price-to-sales ratio is 63.53. PEG ratio is 0.17.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Maze Therapeutics Inc's intrinsic value.